Anchor Capital Advisors LLC Sells 66,456 Shares of GlaxoSmithKline plc (GSK)

Anchor Capital Advisors LLC lowered its stake in GlaxoSmithKline plc (NYSE:GSK) by 10.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 567,827 shares of the pharmaceutical company’s stock after selling 66,456 shares during the quarter. Anchor Capital Advisors LLC’s holdings in GlaxoSmithKline were worth $22,889,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. We Are One Seven LLC increased its position in shares of GlaxoSmithKline by 185.1% in the first quarter. We Are One Seven LLC now owns 2,677 shares of the pharmaceutical company’s stock valued at $105,000 after acquiring an additional 1,738 shares during the last quarter. Kiley Juergens Wealth Management LLC acquired a new stake in shares of GlaxoSmithKline in the second quarter valued at about $113,000. Adviser Investments LLC acquired a new stake in shares of GlaxoSmithKline in the first quarter valued at about $117,000. Toronto Dominion Bank grew its holdings in GlaxoSmithKline by 133.3% during the first quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,800 shares during the period. Finally, Wealthcare Advisory Partners LLC grew its holdings in GlaxoSmithKline by 80.8% during the first quarter. Wealthcare Advisory Partners LLC now owns 3,570 shares of the pharmaceutical company’s stock worth $139,000 after purchasing an additional 1,595 shares during the period. 11.04% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Plc Glaxosmithkline acquired 80,000 shares of GlaxoSmithKline stock in a transaction dated Tuesday, July 17th. The stock was bought at an average price of $12.50 per share, for a total transaction of $1,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have bought 498,048 shares of company stock valued at $6,136,988. Corporate insiders own 10.00% of the company’s stock.



A number of equities analysts recently commented on the company. TheStreet upgraded GlaxoSmithKline from a “c” rating to a “b” rating in a report on Monday, August 6th. Deutsche Bank reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, August 1st. Shore Capital upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, July 27th. Bank of America set a $40.00 price target on GlaxoSmithKline and gave the stock a “hold” rating in a report on Wednesday, July 25th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Friday, July 20th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $40.17.

GlaxoSmithKline stock opened at $39.80 on Wednesday. GlaxoSmithKline plc has a 52 week low of $34.52 and a 52 week high of $42.36. The company has a debt-to-equity ratio of 8.13, a current ratio of 0.94 and a quick ratio of 0.61. The stock has a market cap of $99.57 billion, a P/E ratio of 13.82, a price-to-earnings-growth ratio of 1.98 and a beta of 0.84.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. GlaxoSmithKline had a return on equity of 159.74% and a net margin of 5.51%. The business had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.47 billion. sell-side analysts predict that GlaxoSmithKline plc will post 2.94 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 11th. Stockholders of record on Friday, August 10th will be issued a dividend of $0.496 per share. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.98%. The ex-dividend date is Thursday, August 9th. GlaxoSmithKline’s dividend payout ratio is presently 68.75%.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Average Daily Trade Volume – ADTV

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply